Epirus and Polpharma collaborate on advancing biosimilars portfolio targeting $6 billion addressable market

14 July 2015

USA-based Epirus Biopharmaceuticals (Nasdaq: EPRS) and Polpharma Group, Poland’s largest drugmaker, have signed a multi-product, multi-region profit-sharing collaboration for select Epirus biosimilars. News of the accord pushed Epirus’ shares up 9.4% to $6.99.

The biosimilars include: BOW015 (infliximab, reference biologic Remicade, from Merck & Co), BOW050, (adalimumab, reference biologic Humira, from AbbVie) and BOW070, (tocilizumab, reference biologic Actemra, from Roche), representing $6 billion in innovator sales in the specified territories. The collaboration is focused on the commercialization of Epirus’ biosimilars pipeline in European Union, Middle East, Turkey, Russia and CIS territories (the Territories).

Polpharma Group is a leading generics company based in Poland with annual sales of approximately $1 billion and a strong commercial infrastructure, including a salesforce of over 1,700 employees globally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK